Patients who donot achieve pCRin HER2+disease and haveresidual diseaseget this therapyThis treatmentmodality isalwayscombined withlumpectomysurgeryThis drugclass are thebackbone ofHR+ disease1%Based onOncotype DX,a score of 35will receivethis treatmentThis agent iswell studied fortamoxifeninduced hotflashes inbreast cancerPreferredfrequencyof GnRHagonistsI can give thisagent in highrisk BRCA1/2 mutationfor 1 yearDuration of timepatients willtakeabemaciclib inearly stagediseaseThis agent cancauseendometrialcancer, but hasbone densityprotective effectThe onlysteroidalaromataseinhibitor in itsdrug classThis should bemonitoredroutinely every3-4 monthswhile receivingtrastuzumab Patients withHER2+ diseasecontinuetargetedtherapy for thisdurationPreferredregimen forHR+ diseasefor frail/elderlypatientsThis agent canbe added toLN+ HER2+disease givenwithtrastuzumabThis agent is notused inpremenopausalwomen as endocrinetherapy unless theyalso receive ovariansuppression This subtype ofbreast cancerhas the lowestrelative 5-yearsurvival rate This agentshould beinitiated withneratinib for thefirst 8 weeksThis prodrug isgiven in TNBC forpatients who do notachieve pathologiccomplete responsebased on CREATE-X trialThe ATLAS,AttOM, MA.17Rtrials evaluatedthis durationbenefit ofendocrine therapyUsed asneoadjuvant andadjuvant therapyin high risk TNBCbased on theKEYNOTE 522trialBased onTAILORx, <50years receivechemoendocrinetherapy if theyhave thisOncotypeDx score This CDK 4/6inhibitor is the onlyone in its drugclass also used inearly stage breastcancerThis drug class iscontraindicatedcombined withtrastuzumab-avoid for 7 monthsafter lasttrastuzumab dosePatients who donot achieve pCRin HER2+disease and haveresidual diseaseget this therapyThis treatmentmodality isalwayscombined withlumpectomysurgeryThis drugclass are thebackbone ofHR+ disease1%Based onOncotype DX,a score of 35will receivethis treatmentThis agent iswell studied fortamoxifeninduced hotflashes inbreast cancerPreferredfrequencyof GnRHagonistsI can give thisagent in highrisk BRCA1/2 mutationfor 1 yearDuration of timepatients willtakeabemaciclib inearly stagediseaseThis agent cancauseendometrialcancer, but hasbone densityprotective effectThe onlysteroidalaromataseinhibitor in itsdrug classThis should bemonitoredroutinely every3-4 monthswhile receivingtrastuzumab Patients withHER2+ diseasecontinuetargetedtherapy for thisdurationPreferredregimen forHR+ diseasefor frail/elderlypatientsThis agent canbe added toLN+ HER2+disease givenwithtrastuzumabThis agent is notused inpremenopausalwomen as endocrinetherapy unless theyalso receive ovariansuppression This subtype ofbreast cancerhas the lowestrelative 5-yearsurvival rate This agentshould beinitiated withneratinib for thefirst 8 weeksThis prodrug isgiven in TNBC forpatients who do notachieve pathologiccomplete responsebased on CREATE-X trialThe ATLAS,AttOM, MA.17Rtrials evaluatedthis durationbenefit ofendocrine therapyUsed asneoadjuvant andadjuvant therapyin high risk TNBCbased on theKEYNOTE 522trialBased onTAILORx, <50years receivechemoendocrinetherapy if theyhave thisOncotypeDx score This CDK 4/6inhibitor is the onlyone in its drugclass also used inearly stage breastcancerThis drug class iscontraindicatedcombined withtrastuzumab-avoid for 7 monthsafter lasttrastuzumab dose

BC questions - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
  1. Patients who do not achieve pCR in HER2+ disease and have residual disease get this therapy
  2. This treatment modality is always combined with lumpectomy surgery
  3. This drug class are the backbone of HR+ disease
  4. 1%
  5. Based on Oncotype DX, a score of 35 will receive this treatment
  6. This agent is well studied for tamoxifen induced hot flashes in breast cancer
  7. Preferred frequency of GnRH agonists
  8. I can give this agent in high risk BRCA 1/2 mutation for 1 year
  9. Duration of time patients will take abemaciclib in early stage disease
  10. This agent can cause endometrial cancer, but has bone density protective effect
  11. The only steroidal aromatase inhibitor in its drug class
  12. This should be monitored routinely every 3-4 months while receiving trastuzumab
  13. Patients with HER2+ disease continue targeted therapy for this duration
  14. Preferred regimen for HR+ disease for frail/elderly patients
  15. This agent can be added to LN+ HER2+ disease given with trastuzumab
  16. This agent is not used in premenopausal women as endocrine therapy unless they also receive ovarian suppression
  17. This subtype of breast cancer has the lowest relative 5-year survival rate
  18. This agent should be initiated with neratinib for the first 8 weeks
  19. This prodrug is given in TNBC for patients who do not achieve pathologic complete response based on CREATE-X trial
  20. The ATLAS, AttOM, MA.17R trials evaluated this duration benefit of endocrine therapy
  21. Used as neoadjuvant and adjuvant therapy in high risk TNBC based on the KEYNOTE 522 trial
  22. Based on TAILORx, <50 years receive chemoendocrine therapy if they have this OncotypeDx score
  23. This CDK 4/6 inhibitor is the only one in its drug class also used in early stage breast cancer
  24. This drug class is contraindicated combined with trastuzumab- avoid for 7 months after last trastuzumab dose